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A B S T R A C T
Purpose
Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and
EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive
surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular
subgroup is not known.
Methods
Four independent nonoverlapping retrospective cohorts of posterior fossa ependymomas (n = 820)
were proﬁled using genome-wide methylation arrays. Risk stratiﬁcation models were designed
based on known clinical and newly described molecular biomarkers identiﬁed by multivariable Cox
proportional hazards analyses.
Results
Molecular subgroup is a powerful independent predictor of outcome even when accounting for age
or treatment regimen. Incompletely resected EPN_PFA ependymomas have a dismal prognosis,
with a 5-year progression-free survival ranging from 26.1% to 56.8% across all four cohorts. Al-
though ﬁrst-line (adjuvant) radiation is clearly beneﬁcial for completely resected EPN_PFA, a sub-
stantial proportion of patients with EPN_PFB can be cured with surgery alone, and patients with
relapsed EPN_PFB can often be treated successfully with delayed external-beam irradiation.
Conclusion
The most impactful biomarker for posterior fossa ependymoma is molecular subgroup afﬁliation,
independent of other demographic or treatment variables. However, both EPN_PFA and EPN_PFB
still beneﬁt from increased extent of resection, with the survival rates being particularly poor for
subtotally resected EPN_PFA, even with adjuvant radiation therapy. Patients with EPN_PFB who
undergo gross total resection are at lower risk for relapse and should be considered for inclusion in
a randomized clinical trial of observation alone with radiation reserved for those who experience
recurrence.
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INTRODUCTION
Ependymoma is the third most common posterior fossa tumor of
childhood and a major cause of morbidity and mortality in pe-
diatric oncology, occurring across the entire age spectrum.1-16
Current therapy for posterior fossa ependymoma in children is
aggressive surgical resection followed by involved-ﬁeld radiation,
resulting in 7-year event free-survival of 65%.12,15 Despite the high
mortality rate, trials of cytotoxic chemotherapy have failed to reveal
a clear survival beneﬁt for chemotherapy over surgery and radiation
alone, although deﬁnitive pediatric randomized trials of maintenance
chemotherapy are still recruiting through cooperative groups
(ClinicalTrials.gov identiﬁers: NCT01096368 and NCT02265770).1,5,17
In adults, posterior fossa ependymoma is frequently treated with
surgery alone.18
Numerous publications have suggested that the most powerful
prognostic factor for posterior fossa ependymoma is the extent of
surgical resection or, more appropriately, the amount of residual
tumor after surgery. This has entailed an aggressive surgical approach,
with some oncologists and surgeons tolerating serious neurologic
deﬁcits, including the need for tracheostomies and gastrostomy tubes,
as an inevitable cost in the attempt to achieve tumor-free survival,
including potentially morbid second-look surgery.
Because the majority of ependymomas within the neuroaxis
are histologically similar, historically they had been thought to
compose one disease, but they were subsequently recognized to be
biologically distinct in the supratentorial, posterior fossa, and
spinal compartments of the CNS.19 More recently, integrated
genomic approaches have clearly shown the existence of the fol-
lowing three distinct molecular variants of posterior fossa epen-
dymoma: EPN_PFA, EPN_PFB, and subependymoma. EPN_PFA
occurs primarily in infants and young children, whereas EPN_PFB
occurs primarily in older children and adults.20-23 Subependymomas
are grade 1 tumors with an excellent prognosis restricted to older
adults. Patients with EPN_PFB have an excellent outcome, with
survival rates in excess of 90%, whereas patients with EPN_PFA have
a poor outcome. Curiously, neither EPN_PFA nor EPN_PFB has any
recurrent somatic single nucleotide variants, and both demonstrate
a low rate of mutation across the genome.21 The complete lack of
recurrent somatic single nucleotide variants implies that targeted
therapy using small molecules directed against recurrent mutations
is unlikely to be a successful strategy for patients with posterior fossa
ependymoma. EPN_PFA is characterized by relatively increased
DNA methylation compared with EPN_PFB, and preclinical studies
suggest that epigenetic modulating agents might be beneﬁcial for
patients with EPN_PFA.21
All prior studies of the therapeutic value of cytoreductive
surgery and external-beam radiation done in the premolecular era
have not accounted for subgroup afﬁliation and might therefore be
confounded by clinical differences in response to therapy between
EPN_PFA and EPN_PFB. In addition to extent of resection and
provision of radiotherapy, age at presentation was a strong pos-
terior fossa ependymoma risk factor in the premolecular era lit-
erature. It is unclear whether younger age is an independent risk
factor or is merely a reﬂection of the enrichment of patients with
EPN_PFA in younger cohorts. Thus, it is unclear whether older
patients with EPN_PFAwill do well, whereas younger patients with
EPN_PFB will do poorly. Previous studies from our group and
others have suggested that the two posterior fossa ependymoma
subgroups may have disparate responses to therapy.20,21 To de-
termine the true value of extent of resection, radiation therapy, and
age at presentation as biomarkers in the molecular era, we present
the largest retrospective cohort of posterior fossa ependymomas
ever assembled and determine the validity and strength of known
biomarkers after accounting for molecular subgroup.
METHODS
Three hundred ﬁve posterior fossa ependymomas were obtained from the
Hospital for Sick Children and from collaborating centers from around the
world through the Global Ependymoma Network of Excellence (GENE)
consortium from 1990 to 2014. Samples were all collected in accordance
with the approval of the Hospital for Sick Children Research Ethics Board
and local institutional research ethics boards. To account for unobserved
variables, three independent nonoverlapping validation cohorts were as-
sembled from the prospective St Jude Children’s Research Hospital
(n = 112, RT1 cohort), the Collaborative Ependymoma Research Network
(n = 121, CERN cohort), and the German Cancer Research Center/
Burdenko Neurosurgical Institute (n = 261, Burdenko cohort). Full details of
the cohorts, sample processing, collection of clinical annotations, and
statistical analysis are found in the Appendix (online only).
RESULTS
Demographics of Posterior Fossa Ependymoma Cohorts
Posterior fossa ependymomas from all four cohorts had mo-
lecular subgroup determined using unsupervised hierarchical clus-
tering of genome-wide methylation arrays, as recently described.23 In
total, we analyzed 820 posterior fossa ependymomas, which were
subsequently found to include 678 EPN_PFAs and 142 EPN_PFBs,
with EPN_PFBs more highly enriched in the CERN and Burdenko
cohorts, as reﬂected by the median age (Table 1). Demographics and
treatment details of each of the four cohorts are listed in Table 1. Grade
was not included as a variable because a previous reanalysis of several
prospective cohort studies showed the existing WHO histologic
classiﬁcation to be unreliable as a result of profound intraobserver
variability, confounding its utility in clinical risk stratiﬁcation.24 The
median age of patients with EPN_PFAwas almost identical across all
four cohorts, with a combined median age of 3 years (Appendix Fig
A1, online only; overall age range, 0 to 77 years; GENE: median, 3.6
years; range, 0 to 72 years; St Jude RT1: median, 2.38 years; range, 0.62
to 22.76 years; CERN:median, 4 years; range, 0 to 67 years; Burdenko:
median, 4 years; range, 0 to 65 years). Children younger than age 5
years almost exclusively had EPN_PFA (three EPN_PFB tumors in
patients, 5 years old); however, 45%of pediatric patients age 10 to 17
years had EPN_PFB tumors. Adults largely had EPN_PFB, although
11% of adults had EPN_PFA tumors. Overall, 236 deaths and 420
progression events were observed, and median follow-up time of the
entire cohort was 6.7 years (95% CI, 6.0 to 7.2 years).
Subgroup Affiliation Is the Most Powerful Prognostic
Marker for Posterior Fossa Ependymoma
To determine the prognostic value of ependymoma subgroups,
we performed a Cox proportional hazards regression model across
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all four cohorts incorporating age, extent of surgical resection,
adjuvant external-beam irradiation, subgroup, and cohort stratiﬁ-
cation (Table 2, Appendix Tables A1-A3, online only). No signiﬁcant
predictor-cohort interaction was identiﬁed for any of these variables
with the exception of adjuvant radiation, which had a stronger effect
in the GENE cohort; thus, we proceeded to pool all four cohorts in
a multivariable analysis (Appendix Table A4, online only). After
accounting for treatment variables, subgroup afﬁliation remained
a highly signiﬁcant predictor of progression-free survival (PFS;
hazard ratio [HR], 2.14; 95% CI, 1.31 to 3.49; P = .002, Table 2;
Appendix Tables A1 and A3 report each cohort individually) and
overall survival (OS; HR, 4.30; 95% CI, 1.88 to 9.87; P , .001;
Table 2; Appendix Tables A1 and A3 report each cohort individually).
Administrative censoring at 10 years did not signiﬁcantly alter the
multivariable analysis (Appendix Tables A2 and A3). The HR for
subgroup afﬁliation (HR, 4.30) was the highest of the examined
biomarkers. Extent of resection, adjuvant external-beam irradiation,
andmale sex were also signiﬁcant independent predictors of PFS and
OS, whereas age at diagnosis and delivery of chemotherapy were not.
We then evaluated the survival of patients with EPN_PFA versus
EPN_PFB in each cohort individually. Across the four cohorts,
EPN_PFA had signiﬁcantly worse PFS and OS compared with
EPN_PFB (Table 2; Appendix Fig A2, online only; Appendix
Tables A1 and A2).
EPN_PFA Carries a Poor Prognosis Independent of Age
at Diagnosis
In the premolecular era, age was an important prognostic
factor for patients with posterior fossa ependymoma. We assessed
the relative hazard for EPN_PFA and EPN_PFB depending on age
and found that the relative risk of an EPN_PFA tumor is relatively
constant across all age groups with a slight decrease for adults and is
consistently higher than for EPN_PFB across the entire age spectrum
(Appendix Fig A3, online only).We restricted our survival analysis to
patients older than age 10 years, and EPN_PFA remained a signif-
icant predictor of poor outcome for both 10-year PFS (P = .001) and
10-year OS (P , .001; Appendix Fig A4 and Appendix Table A5,
online only). Finally, to determine whether older children with
EPN_PFA have a poor outcome, we stratiﬁed age as less than or
greater than 10 years and found no signiﬁcant difference in either
PFS or OS, conﬁrming that the poor prognosis attributed to
EPN_PFA is not solely a result of the young age of the cohort
(Fig 1). A similar analysis was done for EPN_PFB, where survival
was stratiﬁed as greater than or less than 18 years with no signiﬁcant
difference in survival, further reafﬁrming that EPN_PFB is
a favorable-risk group independent of age at diagnosis (Fig 1).
As such, we conclude that the poor prognosis of EPN_PFA and
the excellent prognosis of EPN_PFB are independent of age at
diagnosis, conﬁrming the results of the multivariable Cox re-
gression analysis.
Surgical Cytoreduction of EPN_PFA Is Prognostic
Independent of Subgroup
Extent of resection is identiﬁed in multiple publications as
the single most important predictor of outcome for patients with
posterior fossa ependymoma. However, poor-prognosis EPN_PFA
tumors are a difﬁcult surgical challenge as a result of their lateral
location and occurrence in small infants who have a small blood
volume, whereas good-prognosis EPN_PFB tumors are compar-
atively straightforward to resect as a result of their midline location
and occurrence in an older age group. We hypothesized that the
Table 1. Demographic and Treatment Characteristics of All Four Cohorts
Characteristic
No. of Patients (%)
GENE (n = 326) St Jude’s RT1 (n = 112) CERN (n = 121) Burdenko (n = 261)
Median age, years (interquartile range) 3.6 (1.87-7.45) 2.38 (1.57-4.99) 4 (2-25.5) 4 (2-8.5)
Male sex 175 (53.6) 61 (54.5) 63 (52.1) 152 (58.2)
GTR 221 (68.9) 92 (82.1) 68 (56.7) 138 (53.3)
Adjuvant ﬁrst-line radiation 250 (78.6) 112 (100) 72 (59) 196 (75.1)
Adjuvant chemotherapy 138 (44.5) 0 42 (34.7) 164 (62.8)
Disease progression 148 (45.7) 40 (35.7) 72 (59.5) 146 (55.9)
Dead 104 (31.9) 41 (33.9) 28 (25) 63 (24.2)
Subgroup
EPN_PFA 275 (84.4) 104 (92.9) 86 (71.1) 213 (81.6)
EPN_PFB 51 (15.6) 8 (7.1) 35 (28.9) 48 (18.4)
NOTE. Dataweremissing for the following:GTR:GENE, n= 4;CERN, n = 1;Burdenko, n = 2; adjuvantﬁrst-line radiation:GENE, n= 8; adjuvant chemotherapy: GENE, n= 16;
disease progression: GENE, n = 2; and sex: Burdenko, n = 16.
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; GTR, gross total resection (, 5 mm residual disease).
Table 2. Multivariable Cox Proportional Hazards Regression Model of
Progression-Free and Overall Survival
Variable Hazard Ratio 95% CI P
Progression-free survival (n = 777)
Age 0.99 0.98 to 1.00 .13
Male 1.25 1.02 to 1.54 .03
Incomplete resection 1.84 1.49 to 2.28 , .001
Adjuvant ﬁrst-line radiation 0.63 0.49 to 0.79 , .001
Chemotherapy 1.04 0.81 to 1.34 .76
EPN_PFA subgroup 2.14 1.31 to 3.49 .002
Overall survival (n = 778)
Age 0.98 0.96 to 1.00 .12
Male 1.41 1.97 to 1.85 .01
Incomplete resection 2.13 1.60 to 2.82 , .001
Adjuvant ﬁrst-line radiation 0.52 0.38 to 0.72 , .001
Chemotherapy 0.90 0.65 to 1.26 .54
EPN_PFA subgroup 4.30 1.88 to 9.87 , .001
www.jco.org © 2016 by American Society of Clinical Oncology 3
Treatment of Posterior Fossa Ependymoma Subgroups
142.20.16.6
Information downloaded from jco.ascopubs.org and provided by at SICK CHILDRENS HOSPITAL on June 7, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
previously observed therapeutic value for surgical cytoreduction
was confounded by the poor natural history of EPN_PFA tumors,
which are difﬁcult to resect, compared with the benign natural
history of EPN_PFB tumors, which are less difﬁcult to resect.
To determine the relationship between subgroup and extent of
resection after accounting for molecular subgroup, we compared
PFS and OS in each subgroup individually stratiﬁed by extent of
resection. When comparing subtotal resection (STR) versus gross
total resection (GTR) in EPN_PFA, STR was highly predictive of
a dismal PFS and OS (Fig 2 and Appendix Table A6, online only).
In a multivariable Cox proportional hazards model that included
adjuvant chemotherapy and radiation, survival remained dismal
for STR EPN_PFA (Appendix Tables A7 and A8, online only).
Although we observed some variability in the effect of extent of
resection across the four cohorts, we did not observe a statistically
signiﬁcant difference in or heterogeneity of the effect of extent of
resection in EPN_PFA across cohorts (interaction P = .80 for PFS,
P = .53 for OS). Male sex was a signiﬁcant independent predictor of
poor outcome across all four cohorts in GTR in a multivariable
analysis restricted to EPN_PFA, although STR is a high-risk group
in both male and female patients (Appendix Fig A5, online only,
and Appendix Table A7). Within EPN_PFA, female patients with
a GTR had a 5-year PFS of 0.652 (95% CI, 0.581 to 0.732), whereas
male patients with a GTR had a 5-year PFS of 0.455 (95% CI, 0.393
to 0.527).
The value of ﬁrst-line (adjuvant post-surgical) radiotherapy
could only be compared with no radiation in the GENE, CERN,
and Burdenko cohorts, because all patients in the prospective
P = .53
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Fig 1. Survival of EPN_PFA and EPN_PFB stratiﬁed by age. (A) Progression-free survival (PFS) and (B) overall survival (OS) of EPN_PFA stratiﬁed by age greater than or
less than 10 years. (C) PFS and (D) OS of EPN_PFB stratiﬁed by age greater than or less than 18 years. P values determined using log-rank test.
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Fig 2. (A, C, E, and G) Progression-free
survival (PFS) and (B, D, F, and H) overall
survival (OS) of EPN_PFA stratiﬁed by extent
of resection across all four cohorts. CERN,
Collaborative Ependymoma Research Net-
work; GENE, Global Ependymoma Network
of Excellence; GTR, gross total resection;
STR, subtotal resection (. 5 mm residual
disease). P values determined using log-
rank test.
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St Jude RT1 cohort received adjuvant postoperative radiation.
Strikingly, survival for STR EPN_PFA was not different between
those who received ﬁrst-line external-beam radiation and those
who did not in the CERNand Burdenko cohorts (Appendix Fig A6,
online only). In the GENE cohort, there was a statistically sig-
niﬁcant difference by a univariable analysis in patients who did not
receive radiation; however, survival remains poor even in patients
with subtotal resections who received external-beam irradiation.
These data suggest that the beneﬁt of post-surgical ﬁrst-line
adjuvant external-beam irradiation for patients with EPN_PFA
is limited in the face of a subtotal resection and that these patients
should be prioritized for clinical trials of novel therapy.
Patients With GTR EPN_PFB Have an Excellent
Prognosis
As a result of limited patient numbers, we combined patients
with EPN_PFB from the GENE, St Jude RT1, and CERN cohorts
and demonstrated that STR results in a high risk of relapse (10-year
PFS for GTR, 0.740; 95% CI, 0.550 to 0.859; 10-year PFS for STR,
0.50; 95% CI, 0.271 to 0.692). These ﬁndings were conﬁrmed in
a cohort of patients with EPN_PFB treated at the Burdenko In-
stitute (Fig 3). As a result of the similar behavior of the two cohorts
and the relatively small number of patients with EPN_PFB in each
cohort, we combined all patients in our subsequent multivariable
analysis. In a multivariable analysis restricted to EPN_PFB, a similar
P = .4
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Fig 3. Value of adjuvant post-operative ﬁrst-line external-beam irradiation (XRT) in EPN_PFB. (A) Progression-free survival (PFS) and (B) overall survival (OS) of EPN_PFB
across the Global Ependymoma Network of Excellence, St Jude’s, and Collaborative Ependymoma Research Network cohorts. (C) PFS and (D) OS of EPN_PFB across the
Burdenko cohort. P values determined using log-rank test.
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pattern emerges, where an incomplete resection is an independent
predictor of both PFS and OS (Appendix Tables A9 and A10, online
only). However, OS for patients with GTR EPN_PFB is extremely
favorable, with a 10-year OS of 0.961 (95% CI, 0.753 to 0.994),
compared with patients with STR EPN_PFB, who had a 10-year OS
of 0.667 (95% CI, 0.308 to 0.870; Appendix Fig A7, online only).
Interestingly, the PFS for patients with EPN_PFB who did not
receive external-beam irradiation was 0.451 (95% CI, 0.216 to
0.661); however, the OS was 0.823 (95% CI, 0.519 to 0.943). These
data suggest that a subset of patients with EPN_PFB can be cured by
surgery alone after GTR (Fig 3). Of the three nonirradiated patients
with EPN_PFB who died, two had an STR and one had a GTR. A
substantial portion of patients with EPN_PFB who experience re-
currence after initially withholding radiation can potentially be
successfully treated by repeat surgery and delayed delivery of ra-
diation (Fig 3). Indeed, the effect of a GTR versus an STR in
EPN_PFB was signiﬁcant for both the three combined cohorts and
for the Burdenko cohort (P = .02 in univariable Cox regression
A
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Fig 4. Nomogram of (A) progression-free survival (PFS) and (B) overall survival (OS) of posterior fossa ependymoma based on the multivariable Cox proportional hazards
model. Each effect is translated into a risk score. The individual risk scores need to be totaled by the reader. The score sum can be translated into predicted 5- and 10-year
PFS and OS probabilities. EOR, extent of resection; F, female; GTR, gross total resection; M, male; STR, subtotal resection.
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analysis). Because the long-term effects of radiation for posterior
fossa ependymoma in young adults who are cured can be quite
severe,25-28 these data provide the necessary clinical equipoise for
initiation of a clinical trial of initial radiation avoidance in patients
with GTR EPN_PFB ependymoma.
DISCUSSION
We have deﬁned the demographic and prognostic properties of the
two subgroups of posterior fossa ependymoma across the largest
cohort of posterior fossa ependymoma assembled to date. Al-
though three of the cohorts consist of retrospective data, the St
Jude RT1 cohort was prospectively followed and homogeneously
treated. The cohort is of such a large size that it will not likely be repeated
in our lifetime, nor is a prospective clinical trial randomly assigning
extent of resection in posterior fossa ependymoma patients likely.
We have shown that although EPN_PFA occurs primarily in
infants and EPN_PFB is diagnosed primarily in adults, in children
age 10 to 17 years, there is equal representation of both subgroups.
Moreover, in adults, approximately 11% of patients have EPN_PFA.
Across the entire age spectrum, we show that subgroup is the most
powerful predictor of outcome, suggesting that in patients older than
age 5 years, there is signiﬁcant information to be gained in routine
subgrouping of patients with posterior fossa ependymoma. Ex-
tent of resection, although no longer the most powerful predictor
of outcome, remains prognostic in both subgroups. In particular,
patients with STR EPN_PFA constitute a high-risk group with
a poor outcome. Finally, we have shown that a subset of patients
with EPN_PFB can be treated with surgery alone without external-
beam irradiation, suggesting a trial of observation alone may
be warranted in this subset of patients. Overall, in a prediction
model of subgroup, treatment, and extent of resection as depicted
in a nomogram, we ﬁnd that EPN_PFA is the strongest predictor
of poor outcome (Fig 4). Male sex was also an independent
predictor of poor outcome in our analysis across all four cohorts,
which is consistent with previous reports.12 Interestingly the
survival advantage in females is most pronounced in the setting of
GTR EPN_PFA. Amore comprehensive integrated genomic study
will likely be required to clarify this association; however, it is
noteworthy that females with a GTR have 10-year survival rates
approximately 15% higher than males.
Our ﬁnding that patients with STR EPN_PFA have a dismal
outcome has signiﬁcant implications to the design of future clinical
trials. Although a simple proximate solution would be to suggest
GTR in all patients, this is frequently not possible as a result of
brainstem invasion. Additionally, this subset of EPN_PFA seems to
confer the least beneﬁt from adjuvant external-beam irradiation
and could potentially beneﬁt from novel therapies. Previous studies
of chemotherapy have shown only limited activity against posterior
fossa ependymoma, with high-dose chemotherapy with autolo-
gous stem-cell support resulting in 3-year event-free survival of less
than 30%, consistent with the survival we observed.29,30 The role of
adjuvant chemotherapy will require completion and reporting of
long-term outcomes in the open studies of both the European
Society of Pediatric Oncology (SIOPe) and the Children’s Oncology
Group (ACNS0831), where patients are randomly assigned to
maintenance chemotherapy. Our ﬁndings across four independent
cohorts of posterior fossa ependymoma suggest that STR EPN_PFA
should be prioritized for ﬁrst-line investigational agents, such as
DNA demethylase inhibitors and EZH2 inhibitors, to provide an
opportunity to assess activity of these agents prior to radiation.21
Indeed, even patients with GTR EPN_PFA have OS rates of close
to 50%, suggesting aggressive surgeries are not curative, and novel
approaches would beneﬁt this group as well.
We also ﬁnd that STR confers a signiﬁcantly poorer prognosis
in EPN_PFB. Considering that the 10-year OS for EPN_PFB is
greater than 85% with a complete resection, we feel that a GTR
should be attempted where possible. The EPN_PFB data are
limited by small numbers of STR patients and, as such, warrant
some caution in interpretation. Major limitations of our study are
a lack of central review of postoperative imaging in the three
retrospective cohorts, retrospective design of the study without
uniform follow-up imaging to identify progression, and treat-
ment heterogeneity. Indeed, nonenhancing residual tumor can
be missed even with modern postoperative magnetic resonance
imaging. A large prospective radiographic study using modern
three-dimensional magnetic resonance imaging volumetrics with
a receiver operating curve will be needed to determine precisely how
much residual tumor is truly predictive of a poor prognosis.
Finally, our ﬁnding that EPN_PFB can potentially be cured
without external-beam irradiation has profound implications.
Across the EPN_PFB cohort, we demonstrate many patients who
have not experienced recurrence despite the lack of radiation
therapy. Therefore, our data suggest that radiation in EPN_PFB can
be initially withheld and that patients who experience recurrence
can potentially be treated with salvage reresection and radiation.
The ability to successfully treat patients with EPN_PFB with repeat
surgery and radiation therapy is demonstrated by the large
difference between PFS and OS in this patient population.
Considering that the majority of adult posterior fossa epen-
dymoma patients are not treated on open protocols, pro-
spective evaluation will be crucial to determine the optimal
treatment approach. We feel that our data support consider-
ation of a prospective clinical trial of observation alone for
GTR EPN_PFB, which could potentially spare patients the
toxic effects of radiation.31 The age group in which this could confer
the highest beneﬁt would be the older pediatric and adolescent
population, in whom radiation has signiﬁcant effects on learning
and memory, and this approach could signiﬁcantly improve long-
term quality of life in this subset of patients.
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Appendix
Methods
Patient Cohort
All frozen samples were snap frozen and stored at280°C. Both frozen and formalin-ﬁxed parafﬁn-embedded (FFPE) samples
were collected from diagnosis and, in four instances, from relapse. Criteria for inclusion were an institutional histologic diagnosis of
grade 2 or greater ependymoma and location within the posterior fossa. FFPE tissue was collected as scrolls or unstained slides. The
Global Ependymoma Network of Excellence cohort was deemed the discovery cohort. Samples from three additional cohorts were
collected and processed in an identical manner, including central pathologic review by a single pathologist in each of the three
cohorts. Patients from the three additional cohorts have been partially reported in other cohort studies.12,23,24 Subtotal resection
was deﬁned as greater than 5 mm of postoperative residual disease in at least two planes on postoperative magnetic resonance
imaging or postoperative contrast-enhanced computed tomography scan as per the guidelines of the Children’s Oncology Group
based on institutional radiologic reports. A gross total resection was deﬁned as less than 5 mm of postoperative residual disease on
postoperative magnetic resonance imaging or postoperative contrast-enhanced computed tomography based on institutional
radiologic reports. Assessment of clinical variables pertaining to treatment and survival were performed at local institutions blinded
to the molecular subgrouping. Grading was not included as a variable as a result of previous reports showing the extreme in-
terobserver variability of this measure.24
DNA Extraction
Fresh-frozen posterior fossa ependymomas were stored at280°C before processing for extraction of DNA. For frozen samples,
DNA extraction was performed using a proteinase K digestion and phenol:chloroform:isoamyl alcohol extraction and ethanol
precipitation.25 FFPE samples were processed using the Qiagen DNeasy FFPE extraction kit (Qiagen, Hilden, Germany), as per the
manufacturer’s instructions.26 Samples were quantiﬁed using Picogreen (Life Technologies, Waltham, MA).
Genome-Wide DNA Methylation Profiling
All samples were analyzed on the Illumina Inﬁnium HumanMethylation450 BeadChip (Illumina, San Diego, CA) at the
Princess Margaret Genomics Centre (Toronto, Ontario, Canada), the St Jude Children’s Research Hospital (Memphis, TN), or the
German Cancer Research Center (Heidelberg, Germany) according to the manufacturer’s instructions and as previously described.
All analysis was conducted in the R Statistical Environment (v3.1.3; www.r-project.org). Raw data ﬁles (.idat) were processed as
previously described, and ependymoma subgroup afﬁliation was assigned as per a recently released classiﬁer using unsupervised
hierarchical clustering.23 Thirty-ﬁve grade 1 ependymomas (myxopapillary and subependymomas) were excluded from the
analysis based on this classiﬁer. Eleven samples diagnosed as ependymomas by local institutions did not cluster with posterior fossa
ependymoma and were removed from the analysis.
Statistical Analysis
Progression-free survival and overall survival were right censored at 10 years and analyzed using the Kaplan-Meier method, and
P values were determined using the log-rank test. Administrative censoring at 10 years was performed to ensure a reasonable
completeness of follow-up across all four cohorts as a result of declining patient numbers at longer follow-up times. Administrative
censoring resulted in only 1.6% of additionally censored patients at the end of the follow-up period for overall survival. As such,
both continuous and censored data are presented. Survival data are presented as survival estimates including 95% CIs. A pro-
gression event was deﬁned as the earliest time point between two assessment times with clear radiologic progression as reported by
the local institution, and progression-free survival was deﬁned as the interval between the initial diagnosis (typically surgery) and
the progression event. Overall survival was calculated as the time from surgery to the time of death from any cause as reported by the
referring institution. Associations between covariates and risk groups were tested using the Fisher’s exact test. Univariable and
multivariable Cox proportional hazards regression was used to estimate hazard ratios including 95% CIs. In pooled analysis, cohort
was included as a stratiﬁcation variable in the Cox model. In some EPN_PFB subgroup analysis, Firth correction was applied as
a result of monotone likelihoods.27 Age-dependent relative hazards for PFA/PFB subgroups were estimated from a Cox model with
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age and subgroup interaction and a restricted cubic spline functionwith three knots for age to allow for a nonlinear relationship. All
P values reported are two-sided. All statistical analyses were performed in the R statistical environment (v3.1.2), using R packages of
survival (v2.37-7), rms (4.3-1), Coxphf (v1.1), and ggplot2 (v1.0.0).
EPN_PFA EPN_PFB
0
5
10
15
20
Subgroup
Ag
e 
(y
ea
rs
)
St Jude’s Cohort
B
EPN_PFA EPN_PFB
0
10
20
30
40
50
Subgroup
Ag
e 
(y
ea
rs
)
GENE Cohort
A
EPN_PFA EPN_PFB
0
10
20
30
40
50
60
Subgroup
Ag
e 
(y
ea
rs
)
Burdenko Cohort
DC
EPN_PFA EPN_PFB
0
10
20
30
40
50
60
Subgroup
Ag
e 
(y
ea
rs
)
Pa
tie
nt
s 
(%
)
CERN Cohort
E
0%
20%
40%
60%
80%
100%
0–4 5–9 10–17 18+
EPN_PFA
EPN_PFB
Age Group (years)
Fig A1. (A-D) Boxplots of the age distribution of EPN_PFA and EPN_PFB, where boxes represent median and interquartile range and whiskers represent 95% CIs. (E)
Proportion of patients with EPN_PFA and EPN_PFB in each age group. CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of
Excellence.
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Fig A2. Forest plots of EPN_PFA versus EPN_PFB across all cohorts and each cohort individually as a univariate analysis, age-adjusted univariate analysis, and
multivariable analysis for (A) progression-free survival (PFS) and (B) overall survival (OS). CERN, Collaborative Ependymoma Research Network; GENE, Global Epen-
dymoma Network of Excellence.
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(OS).
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ramaswamy et al
142.20.16.6
Information downloaded from jco.ascopubs.org and provided by at SICK CHILDRENS HOSPITAL on June 7, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
P < .001
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
OS
 (p
ro
ba
bi
lit
y)
EPN_PFA
EPN_PFB
54 51 42 38 33 29 28 24 21 16 10EPN_PFA
130 120 111 99 84 76 64 52 43 32 24EPN_PFB
No. at risk
P = .00141
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7 8 9 10
Time Since Diagnosis (years)
PF
S 
(p
ro
ba
bi
lit
y)
EPN_PFA
EPN_PFB
54 48 36 30 25 23 23 20 17 13 7EPN_PFA
130 116 104 91 77 69 58 46 38 28 22EPN_PFB
No. at risk
A B
Fig A4. Survival by subgroup in patients with an age at diagnosis of greater than 10 years for (A) progression-free survival (PFS) and (B) overall survival (OS).
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Fig A5. Sex as a function of extent of resection in EPN_PFA for (A) progression-free survival (PFS) and (B) overall survival (OS). P values were determined using the
log-rank test. GTR, gross total resection; STR, subtotal resection.
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Fig A6. Overall survival (OS) of EPN_PFA for the four cohorts divided by (A, C, and E) gross total resection (GTR) and (B, D, and F) subtotal resection (STR). P values were
determined using the log-rank test. CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; XRT, radiotherapy.
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Fig A7. Progression-free survival (PFS) and overall survival (OS) EPN_PFB stratiﬁed by extent of resection for (A and B) the combined Global Ependymoma Network of
Excellence (GENE), St Jude’s, and Collaborative Ependymoma Research Network (CERN) cohorts and (C and D) the Burdenko Cohort. GTR, gross total resection; STR,
subtotal resection.
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Table A1. Multivariable Cox Proportional Hazards Model of Survival Across All Posterior Fossa Ependymomas
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
GENE cohort (PFS, n = 304; OS, n = 305)
Subgroup EPN_PFA 2.66 (1.14 to 6.23) .02 6.11 (1.38 to 27.01) .02
Age 0.97 (0.95 to 0.99) .008 0.96 (0.93 to 0.99) .02
Incomplete resection 1.87 (1.31 to 2.67) , .001 2.37 (1.55 to 3.64) , .001
Adjuvant ﬁrst-line radiation 0.30 (0.21 to 0.44) , .001 0.29 (0.18 to 0.45) , .001
Adjuvant ﬁrst-line chemotherapy 1.07 (0.74 to 1.55) .72 0.75 (0.47 to 1.20) .23
Male 1.19 (0.86 to 1.66) .30 1.26 (0.83 to 1.89) .28
CERN cohort (PFS, n = 120; OS, n = 120)
Subgroup EPN_PFA 2.08 (0.65 to 6.66) .22 6.95 (1.13 to 42.71) .04
Age 1.00 (0.97 to 1.03) .89 1.01 (0.97 to 1.05) .73
Incomplete resection 1.59 (0.91 to 2.79) .10 1.79 (0.87 to 3.70) .12
Adjuvant ﬁrst-line radiation 0.70 (0.43 to 1.14) .15 0.62 (0.33 to 1.17) .14
Adjuvant ﬁrst-line chemotherapy 0.95 (0.51 to 1.79) .88 0.79 (0.37 to 1.72) .56
Male 1.17 (0.73 to 1.90) .51 2.12 (1.07 to 4.21) .03
St Jude RT1 cohort (PFS, n = 112; OS, n = 112)
Subgroup EPN_PFA 1.40 (0.25 to 7.96) .70 4.94 (0.43 to 698.63) .23
Age 0.99 (0.89 to 1.10) .87 1.05 (0.91 to 1.17) .51
Incomplete resection 2.75 (1.42 to 5.33) .003 3.27 (1.47 to 6.90) .005
Male 2.16 (1.15 to 4.06) .009 2.72 (1.23 to 6.74) .01
Burdenko cohort (PFS, n = 241; OS, n = 241)
Subgroup EPN_PFA 2.49 (0.98 to 6.35) .06 2.72 (0.51 to 14.67) .24
Age 0.99 (0.96 to 1.02) .61 0.98 (0.93 to 1.04) .49
Incomplete resection 2.03 (1.43 to 2.89) , .001 2.00 (1.19 to 3.37) .009
Adjuvant ﬁrst-line radiation 1.11 (0.74 to 1.66) .61 1.08 (0.60 to 1.95) .80
Adjuvant ﬁrst-line chemotherapy 0.99 (0.65 to 1.49) .94 1.38 (0.71 to 2.66) .34
Male 1.10 (0.76 to 1.58) .62 0.85 (0.50 to 1.45) .55
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A2. Multivariable Cox Proportional Hazards RegressionModel of 10-Year
Progression-Free and Overall Survival
Variable Hazard Ratio 95% CI P
Progression-free survival (n = 777)
Age 0.99 0.97 to 1.00 .09
Male 1.25 1.01 to 1.54 .04
Incomplete resection 1.88 1.51 to 2.33 , .001
Adjuvant ﬁrst-line radiation 0.63 0.50 to 0.81 , .001
Adjuvant ﬁrst-line chemotherapy 1.02 0.79 to 1.32 .87
EPN_PFA subgroup 2.18 1.31 to 3.62 .003
Overall survival (n = 778)
Age 0.98 0.96 to 1.00 .13
Male 1.40 1.06 to 1.84 .02
Incomplete resection 2.14 1.61 to 2.84 , .001
Adjuvant ﬁrst-line radiation 0.52 0.38 to 0.71 , .001
Adjuvant ﬁrst-line chemotherapy 0.91 0.66 to 1.27 .6
EPN_PFA Subgroup 4.27 1.86 to 9.81 , .001
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Table A3. Multivariable Cox Proportional Hazards Model of 10-Year Survival Across All Posterior Fossa Ependymoma
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
GENE cohort (PFS, n = 304; OS, n =3 05)
Subgroup EPN_PFA 2.61 (1.04 to 6.53) .04 5.26 (1.17 to 23.60) .03
Age 0.96 (0.93 to 0.99) .005 0.96 (0.92 to 1.00) .03
Incomplete resection 1.90 (1.33 to 2.72) , .001 2.49 (1.61 to 3.87) , .001
Adjuvant ﬁrst-line radiation 0.29 (0.20 to 0.43) , .001 0.27 (0.17 to 0.43) , .001
Adjuvant ﬁrst-line chemotherapy 1.01 (0.69 to 1.47) .96 0.75 (0.47 to 1.22) .25
Male 1.16 (0.83 to 1.61) .40 1.20 (0.79 to 1.82) .40
CERN cohort (PFS, n = 120; OS, n = 120)
Subgroup EPN_PFA 2.08 (0.65 to 6.66) .22 7.52 (1.09 to 51.67) .04
Age 1.00 (0.97 to 1.03) .89 1.00 (0.96 to 1.05) .73
Incomplete resection 1.59 (0.91 to 2.79) .10 1.82 (0.86 to 3.85) .12
Adjuvant ﬁrst-line radiation 0.70 (0.43 to 1.14) .15 0.67 (0.53 to 1.28) .22
Adjuvant ﬁrst-line chemotherapy 0.95 (0.51 to 1.79) .88 0.77 (0.35 to 1.68) .51
Male 1.17 (0.73 to 1.90) .51 2.02 (1.01 to 4.04) .05
St Jude RT1 cohort (PFS, n = 112; OS, n = 112)
Subgroup EPN_PFA 2.87 (0.31 to 26.73) .35 4.68 (0.40 to 662.59) .25
Age 1.00 (0.90 to 1.11) 1.00 1.05 (0.91 to 1.18) .47
Incomplete resection 2.77 (1.42 to 5.38) .003 3.49 (1.56 to 7.45) .003
Male 2.42 (1.25 to 4.67) .009 3.16 (1.38 to 8.30) .006
Burdenko cohort (PFS, n = 241; OS, n = 241)
Subgroup EPN_PFA 2.46 (0.97 to 6.24) .06 2.90 (0.54 to 15.55) .21
Age 0.99 (0.96 to 1.02) .63 0.98 (0.93 to 1.04) .52
Incomplete resection 2.00 (1.40 to 2.84) , .001 2.01 (1.18 to 3.42) .01
Adjuvant ﬁrst-line radiation 1.09 (0.73 to 1.64) .66 1.10 (0.60 to 2.03) .75
Adjuvant ﬁrst-line chemotherapy 1.01 (0.66 to 1.54) .96 1.31 (0.67 to 2.54) .43
Male 1.10 (0.76 to 1.58) .62 0.84 (0.49 to 1.42) .51
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A4. Predictor-Cohort Interaction Likelihood Ratio Test for Both Progression-Free Survival and Overall Survival
Predictor
P
PFS OS
EPN subgroup .35 .84
Age .09 .68
Extent of resection .79 .49
Sex .37 .14
Adjuvant ﬁrst-line chemotherapy .70 .82
Adjuvant ﬁrst-line radiation , .001 .009
NOTE. Values represent the P values for a likelihood ratio test for predictor-cohort interaction.
Abbreviations: OS, overall survival; PFS, progression-free survival.
Table A5. The 5- and 10-Year Survival of Patients With EPN_PFA and EPN_PFB Older Than Age 10 Years
Survival EPN_PFA EPN_PFB
No. of patients 54 128
Median PFS (95% CI)
5-year PFS 0.537 (0.413 to 0.698) 0.828 (0.761 to 0.900)
10-year PFS 0.412 (0.283 to 0.600) 0.622 (0.513 to 0.756)
Median OS (95% CI)
5-year OS 0.705 (0.585 to 0.849) 0.981 (0.955 to 1.000)
10-year OS 0.598 (0.458 to 0.780) 0.868 (0.771 to 0.977)
Abbreviations: OS, overall survival; PFS, progression-free survival.
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Table A6. The 5- and 10-Year Survival of Patients With EPN_PFA Stratiﬁed by GTR and STR Across Four Cohorts
Survival
Median (95% CI)
GENE St Jude’s CERN Burdenko
GTR
5-year PFS 0.467 (0.386 to 0.544) 0.707 (0.596 to 0.793) 0.667 (0.515 to 0.781) 0.453 (0.354 to 0.547)
5-year OS 0.688 (0.605 to 0.756) 0.879 (0.786 to 0.933) 0.739 (0.587 to 0.843) 0.781 (0.682 to 0.853)
10-year PFS 0.425 (0.339 to 0.508) 0.676 (0.561 to 0.767) 0.459 (0.299 to 0.606) 0.369 (0.261 to 0.476)
10-year OS 0.628 (0.533 to 0.710) 0.774 (0.660 to 0.854) 0.567 (0.389 to 0.711) 0.661 (0.526 to 0.766)
STR
5-year PFS 0.370 (0.261 to 0.479) 0.526 (0.287 to 0.719) 0.568 (0.394 to 0.708) 0.261 (0.175 to 0.356)
5-year OS 0.535 (0.413 to 0.643) 0.590 (0.345 to 0.770) 0.681 (0.499 to 0.809) 0.658 (0.540 to 0.753)
10-year PFS 0.259 (0.141 to 0.394) 0.301 (0.102 to 0.531) 0.218 (0.100 to 0.365) 0.143 (0.067 to 0.247)
10-year OS 0.327 (0.194 to 0.467) 0.451 (0.214 to 0.663) 0.401 (0.221 to 0.575) 0.433 (0.280 to 0.577)
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; GTR, gross total resection; OS, overall
survival; PFS, progression-free survival; STR, subtotal resection.
Table A7. Multivariable Cox Proportional Hazards Model of Survival in EPN_PFA
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
All cohorts (PFS, n = 645; OS, n = 646)
Age 0.98 (0.96 to 1.00) .08 0.99 (0.96 to 1.01) .26
Incomplete resection 1.71 (1.37 to 2.14) , .001 2.05 (1.52 to 2.76) , .001
Adjuvant radiation 0.64 (0.50 to 0.82) , .001 0.52 (0.38 to 0.72) , .001
Adjuvant chemotherapy 1.04 (0.81 to 1.35) .74 0.89 (0.63 to 1.26) .51
Male 1.31 (1.05 to 1.62) .02 1.39 (1.04 to 1.85) .02
GENE cohort (PFS, n = 258; OS, n = 259)
Age 0.96 (0.93 to 0.99) .007 0.96 (0.91 to 1.00) .03
Incomplete resection 1.68 (1.17 to 2.42) .005 2.26 (1.46 to 3.49) , .001
Adjuvant radiation 0.31 (0.21 to 0.45) , .001 0.28 (0.18 to 0.45) , .001
Adjuvant chemotherapy 1.08 (0.74 to 1.58) .68 0.78 (0.49 to 1.25) .30
Male 1.10 (0.79 to 1.55) .57 1.17 (0.77 to 1.78) .46
CERN cohort (PFS, n = 86; OS, n = 86)
Age 1.00 (0.96 to 1.04) .92 1.01 (0.97 to 1.06) .53
Incomplete resection 1.63 (0.85 to 3.12) .14 1.80 (0.83 to 3.88) .13
Adjuvant radiation 0.73 (0.43 to 1.25) .25 0.61 (0.31 to 1.18) .14
Adjuvant chemotherapy 0.89 (0.46 to 1.72) .73 0.77 (0.35 to 1.67) .50
Male 1.40 (0.81 to 2.43) .23 2.51 (1.18 to 5.33) .02
St Jude’s RT1 cohort (PFS, n = 104; OS, n = 104)
Age 1.00 (0.90 to 1.12) .94 1.04 (0.91 to 1.19) .61
Incomplete resection 2.71 (0.40 to 5.26) .003 3.26 (1.49 to 7.12) .003
Male 2.42 (1.25 to 4.69) .009 2.86 (1.21 to 6.77) .02
Burdenko cohort (PFS, n = 197; OS, n = 197)
Age 0.99 (0.96 to 1.03) .77 1.01 (0.96 to 1.06) .70
Incomplete resection 1.88 (1.30 to 2.71) , .001 1.84 (1.08 to 3.12) .02
Adjuvant radiation 1.12 (0.74 to 1.70) .60 1.02 (0.56 to 1.85) .94
Adjuvant chemotherapy 0.98 (0.64 to 1.49) .92 1.42 (0.73 to 2.78) .30
Male 1.19 (0.81 to 1.77) .38 0.89 (0.51 to 1.53) .66
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
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Table A8. Multivariable Cox Proportional Hazards Model of 10-Year Survival in EPN_PFA
Variable
PFS OS
HR (95% CI) P HR (95% CI) P
All cohorts (PFS, n = 645; OS, n = 646)
Age 0.98 (0.96 to 1.00) .07 0.99 (0.96 to 1.01) .26
Incomplete resection 1.74 (1.39 to 2.18) , .001 2.05 (1.52 to 2.76) , .001
Adjuvant radiation 0.65 (0.50 to 0.83) , .001 0.52 (0.38 to 0.72) , .001
Adjuvant chemotherapy 1.03 (0.80 to 1.34) .80 0.89 (0.63 to 1.26) .51
Male 1.31 (1.05 to 1.63) .02 1.39 (1.04 to 1.85) .02
GENE cohort (PFS, n = 258; OS, n = 259)
Age 0.95 (0.92 to 0.99) .008 0.96 (0.91 to 1) .03
Incomplete resection 1.74 (1.21 to 2.52) .003 2.26 (1.46 to 3.49) , .001
Adjuvant radiation 0.31 (0.21 to 0.45) , .001 0.28 (0.18 to 0.45) , .001
Adjuvant chemotherapy 1.03 (0.70 to 1.51) .88 0.78 (0.49 to 1.25) .30
Male 1.09 (0.78 to 1.53) .62 1.17 (0.77 to 1.78) .46
CERN cohort (PFS, n = 86; OS, n = 86)
Age 1.00 (0.96 to 1.40) .92 1.01 (0.97 to 1.06) .53
Incomplete resection 1.91 (0.98 to 3.75) .06 1.80 (0.83 to 3.88) .13
Adjuvant radiation 0.84 (0.47 to 1.48) .54 0.61 (0.31 to 1.18) .14
Adjuvant chemotherapy 0.82 (0.42 to 1.61) .57 0.77 (0.35 to 1.67) .50
Male 1.46 (0.82 to 2.59) .20 2.51 (1.18 to 5.33) .02
St Jude’s RT1 Cohort (PFS, n = 104; OS, n = 104)
Age 1.01 (0.90 to 1.12) .9 1.04 (0.91 to 1.19) .61
Incomplete resection 2.77 (1.43 to 5.38) .003 3.26 (1.49 to 7.12) .003
Male 2.59 (1.31 to 5.10) .006 2.86 (1.21 to 6.77) .02
Burdenko cohort (PFS, n = 197; OS, n = 197)
Age 0.99 (0.96 to 1.03) .80 1.01 (0.96 to 1.06) .70
Incomplete resection 1.84 (1.28 to 2.66) .001 1.84 (1.08 to 3.12) .02
Adjuvant radiation 1.10 (0.72 to 1.67) .66 1.02 (0.56 to 1.85) .94
Adjuvant chemotherapy 1.00 (0.65 to 1.54) .99 1.42 (0.73 to 2.78) .30
Male 1.19 (0.81 to 1.77) .38 0.89 (0.51 to 1.53) .66
Abbreviations: CERN, Collaborative Ependymoma Research Network; GENE, Global Ependymoma Network of Excellence; HR, hazard ratio; OS, overall survival; PFS,
progression-free survival.
Table A9. Multivariable Cox Proportional Hazards Model of Survival in EPN_PFB in All Cohorts
Variable
Progression-Free Survival (n = 132) Overall Survival (n = 132)
HR (95% CI) P HR (95% CI) P
Age 0.99 (0.97 to 1.02) .70 0.98 (0.92 to 1.04) .45
Incomplete resection 3.93 (1.78 to 8.68) , .001 11.32 (1.28 to 100.41) .03
Adjuvant radiation 0.49 (0.21 to 1.14) .10 0.53 (0.09 to 3.06) .48
Adjuvant chemotherapy 1.64 (0.45 to 5.92) .45 5.37 (0.45 to 64.12) .18
Male 0.76 (0.37 to 1.59) .47 0.76 (0.15 to 3.79) .74
Abbreviation: HR, hazard ratio.
Table A10. Multivariable Cox Proportional Hazards Model of 10-Year Survival in EPN_PFB in All Cohorts
Variable
Progression Free Survival (n = 132) Overall Survival (n = 132)
HR (95% CI) P HR (95% CI) P
Age 0.99 (0.96 to 1.02) .52 0.97 (0.91 to 1.04) .38
Incomplete resection 4.30 (1.89 to 9.77) , .001 11.06 (1.24 to 98.32) .03
Adjuvant radiation 0.49 (0.21 to 1.16) .10 0.51 (0.09 to 2.99) .45
Adjuvant chemotherapy 1.51 (0.42 to 5.41) .45 4.93 (0.42 to 58.18) .20
Male 0.69 (0.32 to 1.47) .33 0.77 (0.15 to 3.84) .75
Abbreviation: HR, hazard ratio.
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